SLC5A2 and hydrops fetalis: Sodium–glucose co-transporter 2 (SGLT2) inhibitors, which are a newer class of drugs primarily used to treat diabetic patients by inhibiting the glucose reabsorption in the proximal tubule of the kidney, were unexpectedly found to significantly reduce HF hospitalization and cardiovascular death in patients with HF having a reduced ejection fraction (HF-rEF) [13,14].